ライフサイエンスコーパス: paroxysmal atrial fibrillation

1 ge, 66.8 years; 89 men [70.63%]; 20.63% with paroxysmal atrial fibrillation).

2 s (PVs) can successfully treat patients with paroxysmal atrial fibrillation.

3 nts with permanent, and 91% in patients with paroxysmal atrial fibrillation.

4 trial arrhythmia recurrence in patients with paroxysmal atrial fibrillation.

5 catheter ablation to treat either chronic or paroxysmal atrial fibrillation.

6 vein isolation is an effective treatment for paroxysmal atrial fibrillation.

7 single-arm clinical trial of drug-refractory paroxysmal atrial fibrillation.

8 vein isolation is an effective treatment for paroxysmal atrial fibrillation.

9 is a novel, nonthermal ablation modality for paroxysmal atrial fibrillation.

10 atheter for the treatment of drug-refractory paroxysmal atrial fibrillation.

11 rillation who underwent catheter ablation of paroxysmal atrial fibrillation.

12 after pulmonary vein isolation using PFA for paroxysmal atrial fibrillation.

13 y and effectiveness of catheter-based PFA in paroxysmal atrial fibrillation.

14 and simple pulmonary vein isolation to treat paroxysmal atrial fibrillation.

15 er ablation as treatment for drug-refractory paroxysmal atrial fibrillation.

16 in symptomatic patients with drug-refractory paroxysmal atrial fibrillation.

17 or pulmonary vein isolation in patients with paroxysmal atrial fibrillation.

18 ssociated with postblanking AT recurrence in paroxysmal atrial fibrillation.

19 al-time CF in the treatment of patients with paroxysmal atrial fibrillation.

20 ersus RF ablation for treating patients with paroxysmal atrial fibrillation.

21 pulmonary vein isolation in 46 patients with paroxysmal atrial fibrillation.

22 abbreviated QT interval (200 ms) on ECG and paroxysmal atrial fibrillation.

23 prevalent approach for catheter ablation of paroxysmal atrial fibrillation.

24 apy as first-line treatment in patients with paroxysmal atrial fibrillation.

25 tion model for NPV triggers in patients with paroxysmal atrial fibrillation.

26 nary vein isolation in persistent as well as paroxysmal atrial fibrillation.

27 ion, there is no benefit of CFAE ablation in paroxysmal atrial fibrillation.

28 or laserballoon PVI (cryoballoon: n=100: 50 paroxysmal atrial fibrillation + 50 persistent AF versus

29 persistent AF versus laserballoon: n=100: 50 paroxysmal atrial fibrillation + 50 persistent AF).

30 59%) male, 47.3+/-17 years old, having vagal paroxysmal atrial fibrillation 58 (70%) or neurocardioge

31 At 30 centers, 277 patients with paroxysmal atrial fibrillation (61.5+/-10.3 years of age

32 on and find out whether it could improve the paroxysmal atrial fibrillation ablation results in human

33 he US Food and Drug Administration (FDA) for paroxysmal atrial fibrillation (AF) ablation and used in

34 Transformation from persistent to paroxysmal atrial fibrillation (AF) after ablation sugge

35 was a 4-week diagnostic study of adults with paroxysmal atrial fibrillation (AF) and current alcohol

36 A) after pulmonary vein antrum isolation for paroxysmal atrial fibrillation (AF) and rhythm outcome d

37 igoxin is commonly prescribed in symptomatic paroxysmal atrial fibrillation (AF) but has never been e

38 Maintenance of paroxysmal atrial fibrillation (AF) by fast rotors in th

39 0 years numerous studies on the treatment of paroxysmal atrial fibrillation (AF) by right and left at

40 Patients with paroxysmal atrial fibrillation (AF) eligible for AAD the

41 e of pulmonary vein (PV) antrum isolation in paroxysmal atrial fibrillation (AF) patients over more t

42 cts with symptomatic, persistent/high-burden paroxysmal atrial fibrillation (AF) were enrolled at 6 c

43 n the atria of patients with persistent than paroxysmal atrial fibrillation (AF), and left atrial (LA

44 Unlike for paroxysmal atrial fibrillation (AF), pulmonary vein isol

45 In patients with paroxysmal atrial fibrillation (AF), rhythm control with

46 nary veins is often effective in eliminating paroxysmal atrial fibrillation (AF).

47 is commonly found in individuals at risk for paroxysmal atrial fibrillation (AF).

48 nt triggers and a perpetuation mechanism for paroxysmal atrial fibrillation (AF).

49 oth balloons in patients with persistent and paroxysmal atrial fibrillation (AF).

50 inuous oral anticoagulation in patients with paroxysmal atrial fibrillation (AF).

51 patients with drug refractory, symptomatic, paroxysmal atrial fibrillation (AF).

52 c perturbations frequently antecede onset of paroxysmal atrial fibrillation (AF).

53 atrial activation as seen clinically during paroxysmal atrial fibrillation (AF).

54 stantial number of arrhythmia recurrences in paroxysmal atrial fibrillation (AF).

55 lmonary vein (PV) isolation in patients with paroxysmal atrial fibrillation (AF).

56 ein (PV) activity has been shown to maintain paroxysmal atrial fibrillation (AF).

57 observed in 70 patients (16.1%) before TAVR: paroxysmal atrial fibrillation (AF)/atrial tachycardia (

58 Paroxysmal atrial fibrillation and atrial tachycardia we

59 ion, diabetes mellitus, dementia, history of paroxysmal atrial fibrillation and earlier year of impla

60 Among patients with paroxysmal atrial fibrillation and hypertension, renal d

61 Patients with history of paroxysmal atrial fibrillation and indication for corona

62 We randomly assigned 294 patients with paroxysmal atrial fibrillation and no history of antiarr

63 -level data on first-time PFA procedures for paroxysmal atrial fibrillation and nonparoxysmal atrial

64 arrhythmia rate is low, the relative risk of paroxysmal atrial fibrillation and NSVT during sleep is

65 t Health Study (n = 2,816) were screened for paroxysmal atrial fibrillation and NSVT.

66 of extrinsic sympathovagal nerves eliminated paroxysmal atrial fibrillation and paroxysmal atrial tac

67 n set comprised pulmonary vein isolation for paroxysmal atrial fibrillation and pulmonary vein isolat

68 In group 2, the frequencies of paroxysmal atrial fibrillation and tachycardia during ac

69 ad higher basal heart rates, higher rates of paroxysmal atrial fibrillation, and lower platelet count

70 ing results in sympathetic hyperinnervation, paroxysmal atrial fibrillation, and paroxysmal atrial ta

71 king at least 1 antihypertensive medication, paroxysmal atrial fibrillation, and plans for ablation w

72 e treatment of patients with drug-refractory paroxysmal atrial fibrillation, and there was no signifi

73 outcome of the Angiotensin II-Antagonist in Paroxysmal Atrial Fibrillation (ANTIPAF) trial, which in

74 Four cases of (paroxysmal) atrial fibrillation are presented, two cases

75 tepwise analysis including age, male gender, paroxysmal atrial fibrillation, basal QTc values, basal

76 tepwise analysis including age, male gender, paroxysmal atrial fibrillation, basal QTc values, basal

77 blanking period after catheter ablation for paroxysmal atrial fibrillation but calls into question t

78 ctory results for the long-term treatment of paroxysmal atrial fibrillation, but not for the treatmen

79 Pulmonary vein isolation using PFA for paroxysmal atrial fibrillation does not cause thermal le

80 brillation has a lower success rate than for paroxysmal atrial fibrillation, due to structural, elect

81 Most paroxysmal atrial fibrillation events were preceded only

82 which patients 18 to 80 years of age who had paroxysmal atrial fibrillation for which they had not pr

83 pain syndrome, hypertension, and refractory paroxysmal atrial fibrillation, for which she had underg

84 or pulmonary vein isolation in patients with paroxysmal atrial fibrillation has demonstrated encourag

85 Many elderly patients with recurrent paroxysmal atrial fibrillation have high rates of stroke

86 for ablation of drug refractory, symptomatic paroxysmal atrial fibrillation in 172 participants recru

87 randomly assigned patients with symptomatic paroxysmal atrial fibrillation in a 1:1 ratio to undergo

88 l, we assigned patients with drug-refractory paroxysmal atrial fibrillation in a 1:1 ratio to undergo

89 veins (PVs) allows for successful control of paroxysmal atrial fibrillation in many patients.

90 However, paroxysmal atrial fibrillation is often asymptomatic and

91 ersus single tip wide area catheter ablation-paroxysmal atrial fibrillation is the first multinationa

92 edical management of individuals with covert paroxysmal atrial fibrillation, is a topic of intensive

93 ad higher basal heart rates, higher rates of paroxysmal atrial fibrillation, lower platelet count.

94 lloon Pulmonary Vein Ablation of Symptomatic Paroxysmal Atrial Fibrillation (MACPAF) study, serial 3-

95 Thirty-seven patients with paroxysmal atrial fibrillation (median age, 63.0 [interq

96 ustained ventricular tachycardia [n=1], fast paroxysmal atrial fibrillation [n=1], symptomatic bradyc

97 l (VytronUS Ablation System for Treatment of Paroxysmal Atrial Fibrillation; NCT03639597) in patients

98 RAPULSE Endocardial Ablation System to Treat Paroxysmal Atrial Fibrillation; NCT03714178).

99 isolation in the treatment of patients with paroxysmal atrial fibrillation, novel catheter designs t

100 Persistent or paroxysmal atrial fibrillation occurred in 7%, the major

101 for atrial fibrillation and represented with paroxysmal atrial fibrillation or atrial tachycardia und

102 d left atrial pacing was performed to induce paroxysmal atrial fibrillation or atrial tachycardia.

103 s are temporally associated with episodes of paroxysmal atrial fibrillation or NSVT.

104 In patients with drug-refractory paroxysmal atrial fibrillation or short-standing persist

105 line within 5 years (odds ratio [OR]: 12.7), paroxysmal atrial fibrillation (OR: 5.19), subtherapeuti

106 In comparison, group 2 dogs had no paroxysmal atrial fibrillation (P=0.046) or paroxysmal a

107 The associations of paroxysmal atrial fibrillation (PAF) and persistent atri

108 t the hypothesis that PP1 is dysregulated in paroxysmal atrial fibrillation (PAF) at the level of its

109 Paroxysmal atrial fibrillation (PAF) detection was highe

110 atients; 60 patients undergoing ablation for paroxysmal atrial fibrillation (PAF), 30 patients underg

111 as a mechanism for initiating and sustaining paroxysmal atrial fibrillation (PAF).

112 LACA) to encircle the PVs both may eliminate paroxysmal atrial fibrillation (PAF).

113 become accepted therapy for drug-refractory paroxysmal atrial fibrillation (PAF).

114 heter ablation is important for treatment of paroxysmal atrial fibrillation (PAF).

115 n PVI or GP ablation alone, in patients with paroxysmal atrial fibrillation (PAF).

116 g persistent atrial fibrillation (LPeAF), or paroxysmal atrial fibrillation (PAF); if right atrial si

117 The inspIRE study (Study for Treatment of Paroxysmal Atrial Fibrillation [PAF] by Pulsed Field Abl

118 of the inspIRE study (Study for Treatment of Paroxysmal Atrial Fibrillation [PAF] by Pulsed-field Abl

119 ated in cryptogenic stroke, including occult paroxysmal atrial fibrillation, patent foramen ovale, ao

120 ted States-based drug-refractory symptomatic paroxysmal atrial fibrillation patient population.

121 This study includes the first 200 paroxysmal atrial fibrillation patients treated with the

122 Paroxysmal atrial fibrillation patients underwent PV iso

123 n a homogenous population of 150 consecutive paroxysmal atrial fibrillation patients using CARTO and

124 multicenter clinical feasibility phase (n=30 paroxysmal atrial fibrillation patients).

125 Compared to patients with paroxysmal atrial fibrillation, patients with persistent

126 There were 4+/-2 episodes of paroxysmal atrial fibrillation per day and 10+/-3 episod

127 Among patients with symptomatic paroxysmal atrial fibrillation, PFA was noninferior to c

128 age, female sex, left ventricular function, paroxysmal atrial fibrillation, prior bleeding, lower se

129 en were older and had a higher prevalence of paroxysmal atrial fibrillation, prior stroke, and uncont

130 Among patients with paroxysmal atrial fibrillation receiving a catheter-base

131 predict the trigger origins in patients with paroxysmal atrial fibrillation receiving catheter ablati

132 n autonomic activation and the mechanisms of paroxysmal atrial fibrillation remains unclear.

133 before radiofrequency catheter ablation for paroxysmal atrial fibrillation significantly reduces the

134 CH Catheter for the Treatment of Symptomatic Paroxysmal Atrial Fibrillation (SMART-AF) trial using sh

135 The Sustained Treatment of Paroxysmal Atrial Fibrillation (STOP AF) trial randomize

136 nt Cryoablation Balloon for the Treatment of Paroxysmal Atrial Fibrillation [Stop AF]; NCT00523978).

137 In 20 patients with paroxysmal atrial fibrillation, synchronized high freque

138 In patients with symptomatic paroxysmal atrial fibrillation that has not responded to

139 In patients treated for paroxysmal atrial fibrillation, the pulmonary vein (PV)

140 receiving initial treatment for symptomatic, paroxysmal atrial fibrillation, there was a significantl

141 Fibrillation; NCT03639597) in patients with paroxysmal atrial fibrillation, this LICU system was eva

142 dergoing radiofrequency catheter ablation of paroxysmal atrial fibrillation to receive remote IPC or

143 In the enrolled 52 patients with paroxysmal atrial fibrillation, ultrasound M-mode-based

144 nfiguration in 38 patients with a history of paroxysmal atrial fibrillation undergoing an invasive el

145 A total of 401 patients with paroxysmal atrial fibrillation undergoing pulmonary vein

146 pulmonary vein isolation in 25 patients with paroxysmal atrial fibrillation undergoing wide-area circ

147 Forty patients with paroxysmal atrial fibrillation underwent mandatory repea

148 T, symptomatic drug-refractory patients with paroxysmal atrial fibrillation underwent PFA or thermal

149 m, patients with drug-refractory symptomatic paroxysmal atrial fibrillation underwent pulmonary vein

150 ive patients (61+/-8 years old, 41 men) with paroxysmal atrial fibrillation underwent PVI using Carto

151 atients (age, 57+/-12 years; 28% female; 63% paroxysmal atrial fibrillation) underwent 198 ablations

152 ke or TIA who were 55 years of age or older, paroxysmal atrial fibrillation was common.

153 Persistent or paroxysmal atrial fibrillation was observed in OHT patie

154 Paroxysmal atrial fibrillation was the predominant recur

155 is study, in patients undergoing ablation of paroxysmal atrial fibrillation, was to: (1) identify fac

156 apy as first-line treatment in patients with paroxysmal atrial fibrillation, we found no significant

157 patients with symptomatic, drug-refractory, paroxysmal atrial fibrillation were enrolled in a prospe

158 Patients with paroxysmal atrial fibrillation were randomized to MEA (6

159 age 59+/-10, CHA(2)DS(2)-VASc 1.3+/-1.1, 54% paroxysmal atrial fibrillation) were allocated to the PV

160 e 62.9+/-10.3 years, 35.1% women, 47.2% with paroxysmal atrial fibrillation) were enrolled and random

161 inferiority study included 140 patients with paroxysmal atrial fibrillation, which was refractory to

162 iofrequency energy delivery in patients with paroxysmal atrial fibrillation who undergo PVI and leads

163 e retrospectively analyzed 521 patients with paroxysmal atrial fibrillation who underwent catheter ab

164 Initial treatment of paroxysmal atrial fibrillation with catheter cryoballoon